Faron Pharmaceuticals Oy PDMR Shareholding (8816Q)
05 December 2016 - 6:46PM
UK Regulatory
TIDMFARN
RNS Number : 8816Q
Faron Pharmaceuticals Oy
05 December 2016
Faron Pharmaceuticals Oy
("Faron" or the "Company")
PDMR Shareholding
TURKU - FINLAND, 5 December 2016 - Faron Pharmaceuticals Ltd
("Faron") (LON: FARN), the clinical stage biopharmaceutical
company, announces that on 16th and 19th September 2016 Dr Matti
Karvonen, Medical Director of Faron, acquired ordinary shares in
Faron on his own behalf and on behalf of his closely associated
persons. As a member of the management group of Faron, Dr Karvonen
is regarded as a person discharging managerial responsibility
("PDMR").
PDMR Shares purchased
Matti Karvonen 25,770
25,770
The notification below, which has been made in accordance with
the requirements of the EU Market Abuse Regulation, provides
further detail.
For more information please contact:
Faron Pharmaceuticals Ltd
Katja Wallenlind
Phone +358 (50) 577 4807
E-mail: katja.wallenlind@faronpharmaceuticals.com
Hume Brophy, PR
Mary Clark, Eva Haas, Hollie Vile
Phone: +44 207 862 6390
E-mail: faron@humebrophy.com
Cairn Financial Advisers LLP, Nominated Adviser
Emma Earl, Tony Rawlinson, Rebecca Anderson
Phone: +44 207 213 0880
Panmure Gordon (UK) Limited, Joint Broker
Freddy Crossley, Duncan Monteith (Corporate Finance)
Tom Salvesen (Corporate Broking)
Phone: +44 207 886 2500
Whitman Howard Limited, Nominated Broker
Ranald McGregor-Smith, Francis North
Phone: +44 207 659 1234
About Faron Pharmaceuticals Ltd
Faron is a clinical stage biopharmaceutical company developing
novel treatments for medical conditions with significant unmet
needs. The Company currently has a pipeline focusing on acute organ
traumas, cancer immunotherapy and vascular damage. The pipeline is
built on Faron's scientific knowledge and control of the
endothelial barrier, the membrane of cells lining blood and
lymphatic vessels to separate blood content from tissues. The
Company's lead candidate Traumakine(R) is in development for the
treatment of Acute Respiratory Distress Syndrome ("ARDS"), a rare,
severe, life-threatening medical condition characterised by
widespread inflammation in the lungs. Traumakine is currently in
pan-European (INTEREST) and Japanese pivotal Phase III studies.
Additionally, Faron is developing Clevegen(R) a ground breaking
pre-clinical anti-Clever-1 antibody. Clevegen has the ability to
convert the immune environment around a tumour from being immune
suppressive to immune stimulating. This novel macrophage-directed
immuno-oncology approach is called Tumour Immunity Enabling
Technology ("TIET") and can be used alone or in combination with
other immune checkpoint molecules for the treatment of cancer
patients. New application opportunities related to TIET cover
chronic infections and inefficient vaccination. Based in Turku,
Finland, Faron Pharmaceuticals is listed on AIM under the ticker
'FARN'. Further information is available at
www.faronpharmaceuticals.com
Notification of a Transaction pursuant to Article 19(1) of Regulation
(EU) No. 596/2014
---------------------------------------------------------------------------------------------------
1 Details of the person discharging managerial responsibilities/person
closely associated
----- --------------------------------------------------------------------------------------------
a. Name 1. Matti Karvonen
-------------------------------------------------------
2 Reason for notification
----- ----------------------------------- -------------------------------------------------------
a. Position/Status Person discharging managerial responsibilities
----- ----------------------------------- -------------------------------------------------------
b. Initial notification/ Initial Notification
Amendment
----- ----------------------------------- -------------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
--------------------------------------------------------------------------------------------
a. Name Faron Pharmaceuticals Oy
----- ----------------------------------- -------------------------------------------------------
b. LEI 7437009H31TO1DC0EB42
----- ----------------------------------- -------------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
----- --------------------------------------------------------------------------------------------
a. Description of Ordinary shares
the financial
instrument, type ISIN: FI4000153309
of instrument
Identification
Code
----- ----------------------------------- -------------------------------------------------------
b. Nature of the Purchase of Ordinary Shares
transaction
----- ----------------------------------- -------------------------------------------------------
c. Price(s) and volume(s) Price(s) Volume(s)
----- ----------------------------------- -------------------------------- ----------------
1. 3.04EUR 16,770
-------------------------------------------------------------------------- ----------------
d. Aggregated information
- Aggregated Volume N/a (Single transaction)
- Price
----- ----------------------------------- -------------------------------------------------------
e. Date of the transaction 16 September 2016
----- ----------------------------------- -------------------------------------------------------
f. Place of the transaction Turku
----- ----------------------------------- -------------------------------------------------------
a. Description of Ordinary shares
the financial
instrument, type ISIN: FI4000153309
of instrument
Identification
Code
---- -------------------------- ------------------------------------
b. Nature of the Purchase of Ordinary Shares
transaction
---- -------------------------- ------------------------------------
c. Price(s) and volume(s) Price(s) Volume(s)
---- -------------------------- ------------------- ----------
1. EUR2.78 9,000
--------------------------------------------------- ----------
d. Aggregated information
- Aggregated Volume N/a (Single transaction)
- Price
---- -------------------------- ------------------------------------
e. Date of the transaction 19 September 2016
---- -------------------------- ------------------------------------
f. Place of the transaction Turku
---- -------------------------- ------------------------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHFSEFWEFMSEEE
(END) Dow Jones Newswires
December 05, 2016 02:46 ET (07:46 GMT)
Faron Pharmaceuticals Oy (LSE:FARN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Faron Pharmaceuticals Oy (LSE:FARN)
Historical Stock Chart
From Apr 2023 to Apr 2024